Merck expands Bengaluru plant to strengthen global filtration supply chain

New filtration lines will boost global drug supply and strengthen India’s role in Merck’s manufacturing network

Toray develops membrane doubling filtration for biopharmaceutical manufacturing processes

The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization

3M to invest nearly $150 million on expanding biopharma filtration capabilities

The investment will include facility and equipment improvements and the addition of 60 full-time positions in 3M manufacturing facilities in Europe.

Merck KGaA to expand its membrane and filtration manufacturing facility in Ireland

The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland

Sir Ganga Ram Hospital launches dialysis center in Gurgaon to expand renal care access

New facility in Sector 51 offers advanced, affordable, and patient-centric dialysis services for NCR patients

Finerenone hits major goal in Phase III FIND-CKD trial

There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk

Vivere Oncotherapies secures more than $10M to tackle hard-to-treat ‘cold’ tumors

AB Science secures US patent for Masitinib in sickle cell disease till 2040

Masitinib targets mast cells, which play a critical role in severe forms of SCD and its complications, including vaso-occlusive crises, acute chest syndrome, and pain

Hansa Biopharma submits FDA application for kidney transplant desensitization treatment

If approved, imlifidase has the potential to transform the kidney transplant landscape by enabling highly sensitized patients to also have access to a potentially life-changing kidney transplant

Lords Mark bets big on AI-driven dialysis tech, buys 85% stake in Renalyx Health

Renalyx will continue operating as an independent unit within the group